Tedisamil: master switch of nature?

Bibliography

• KJEKSHUS S: Heart rate reduction a mechanism of benefit. Eur. Heart J. (1987) 8 (Suppl. 0:115–122.
   Google Scholar
• KUHL UG, BUSCHMANN G: Cardiovascular profile of KC 8857 in comparison with other cardioselective agents. Mol Cell. Cardiol (1987) 19 (Suppl.
   Google Scholar
• NEMETH M, VIRAG L, HALA 0 et al.: The cellular electro-physiological effects of tedisamil in human atrial and ventricular fibers. Cardiovasc. Res. (1996) 31:146–248.
   Google Scholar
• SCHON U, ANTEL J, BRUCKNER R, MESSINGER J, FRANKE R, GRUSKA A: Synthesis, pharmacological characteri-zation and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispodines: derivatives with specific bradycardic activity. J Med. Chem. (1998) 41:318–331.
   PubMed Web of Science ®Google Scholar
• FENG J, WANG Z, LI GR, NATTEL S: Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes. j Pharmacol. Exp. Ther. (1997) 2 81 :384–392.
   Google Scholar
• DOGGRELL SA, NAND V, BROWN L: Positive inotropic responses to potassium channel blockers. CUIT. Res. Ion Channel Modulators 3:77–86.
   Google Scholar
• DUKES ID, MORAD: Tedisamil inactivates transient outward K+ current in rat ventricular myocytes. Am. J Physiol. (1989) 2 5 7:H1746–H1749.
   Google Scholar
• BERGER F, BORCHARD U, HAFNER D, WEIS TM: Different inhibition patterns of tedisamil for fast and slowly inactivation transient outward current in rat ventricular myocytes. Naunyn-Schiedeberg's Arch. Pharmacol. (1998) 357:291–298.
   PubMed Web of Science ®Google Scholar
• WETTVVER E, HIMMEL HM, AMOS GJ, LI Q, METZGER F, RAVENS U: Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Br. J. Pharmacol. (1998) 125:659–666.
   PubMed Web of Science ®Google Scholar
• DUKES ID, CLEEMANN L, MORAD M: Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. J. Pharmacol Exp. Ther. (1990) 254:560–569.
   PubMed Web of Science ®Google Scholar
• FAIVRE JR, BRIL A: Tedisamil inhibition of ATP-sensitive K+channels in adult rat ventricular cells. Mol. Cell. Cardiol. (1992) 24:S40.
   Google Scholar
• CHI L, PARK JL, FRIEDRICHS GS et al.: Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br. Pharmacol (1996) 117:1261–1269.
   PubMed Web of Science ®Google Scholar
• FAIVRE JF, ROUANET S, BRIL A: Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031 and BRL-32872 on protein kinase-activated chloride current in guinea pig ventricular myocytes. J. Cardio-vasc. Pharmacol. (1998) 31:551–557.
   PubMed Web of Science ®Google Scholar
• PFRUNDER D, KREYE VA: Tedisamil inhibits the delayed rectifier K+ current in single smooth muscle cells of the guinea-pig portal vein. Pflugers Arch. (1992) 421:22–25.
   PubMed Web of Science ®Google Scholar
• PFRUNDER D, KREYE VA: Tedisamil blocks singlylarge-conductance Ca2+-activated K+ channels in membrane patches from smooth muscle cells of the guinea-pig portal vein. Pflugers Arch. (1991) 418:308–312.
   PubMed Web of Science ®Google Scholar
• BRAY K, QUAST U: Tedisamil (KC 8857) differentiallyinhibits the 86Rb+ efflux-stimulating and vasorelax ant properties of cromakalim. Eur. j Pharmacol. (1991) 2 0 0:163–165.
   Google Scholar
• BEATCH GN, ABRAHAM S, MACLEOD BA, YOSHIDA NR, WALKER MJ: Antiarrhythmic properties of tedisamil (KC8857), a putative transient outwardcurrentblocker. Br. J. Pharmacol. (1991) 102:13–18.
   PubMed Web of Science ®Google Scholar
• •Key reference to anti-arrhythmic activity.
   Google Scholar
• DORIAN P, NEWMAN D: Tedisamil increases coherenceduring ventricular fibrillation and decreases defibril-lation energy requirements. Cardiovasc. Res. (1997) 33:485–494.
   PubMed Web of Science ®Google Scholar
• NEMETH M, VARRO A, VIRAG L, HLA 0, THORMAHLEN D,PAPP JG: Frequency-dependent cardiac electr ophysiol-ogic effects of tedisamil: comparison with quinidine and sotalol. J. Cardiovasc. Pharmacol. Ther. (1997) 2:273–284.
   PubMedGoogle Scholar
• BARGHEER K, BODE F, KLEIN HU, TRAPPE HJ, FRANZ MR, LICHTLEN PR: Prolongation on monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur. Heart" (1994) 15:1409–1414.
   PubMed Web of Science ®Google Scholar
• CARMELIET E: Use-dependent block of the delayed K+ current in rabbit ventricular myocytes. Cardiovasc. Drugs Ther. (1993) 7 (Sunni. 3):599–604.
   Google Scholar
• LATHROP DA: Electro-mechanical characterisation ofracemic sotalol and its optical isomers on isolated canine ventricular trabecular muscles and Purkinje strands. Can. J. Physiol Pharmacol. (1985) 63:1506–1512.
   PubMed Web of Science ®Google Scholar
• BOSCH RF, GASPO R, BUSCH AE, LANG HJ, LI GR, NATTEL S: Effects of chromanol 293B, a selective blocker of the slow, component of the delayed rectifier Iecurrent on human and guinea pig ventricular myocytes. Cardio-vasc. Res. (1998) 38:441–450.
   PubMed Web of Science ®Google Scholar
• GROH WJ, GIBSON KJ, MAYLIE JG: Comparison of the rate-dependent properties of the class III antiar-rhythmic agents azimilide (NE-10064) and E-4031: considerations of the mechanism of reverse rate-dependent action potential prolongation. J. Cardiovasc. Electrophysiol. (1997) 8:529–536.
   PubMed Web of Science ®Google Scholar
• BRIL A, LANDAIS L, GROUT B: Actions and interactionsof E-4031 and tedisamil on reperfusion-induced arrhythmias and QT interval in rat in vivo. Cardiovasc. Drugs Ther. (1993) 2:233–240.
   Google Scholar
• FRIEDRICHS GS, ABREU JN, COUSINS GR, CHI L, BORLAKJ, LUCCHESI BR: Tedisamil attenuates ventricular fibril-lation in a conscious canine model of sudden cardiac death. J. Cardiovasc. Pharmacol. Ther. (1996) 1:313–324.
   PubMedGoogle Scholar
• HERMANN HP, OHLER A, JUST H, HASENFUSS G: Cardiacand hemodynamic effects of the sinus node inhibitor tedisamil dihydrochloride in patients with congestive heart failure due to dilated cardiomyopathy. j Cardio-vasc. Pharmacol. (1998) 3 2:969–972.
   Google Scholar
• WALLACE AA, STUPIENSKI RF 3RD, BASKIN EP et al.: Cardiac electrophysiologic and antiarrhythmic actions of tedisamil. j Pharmacol. Exp. Ther. (1995) 273:168–175.
   Google Scholar
• BASKIN EP, LYNCH JJ, JR.: Differential atrial versus ventricular activities of class III potassium channel blockers. j Pharmacol. Exp. Ther. (1998) 285:135–142.
   Google Scholar
• TSUCHIHASHI K, CURTIS MJ: Influence of tedisamil on the initiation and maintenance of ventricular fibrilla-tion: chemical defibrillation by Ito blockade? Cardio-vasc. Pharmacol. (1991) 18:445–456.
   Web of Science ®Google Scholar
• JOSEPHSON IR, SANCHEZ-CHAPULA J, BROWN AM: Early outward current in rat ventricular cells. Circ. Res. (1984) 54:157–172.
   PubMed Web of Science ®Google Scholar
• GILES WR, IMIAZUMI Y: Comparison of potassium currents in rabbit atrial and ventricular cells. J. Physiol. (1988) 405:123–145.
   PubMed Web of Science ®Google Scholar
• FRIEDRICHS GS, ABREU JN, DRISCOLL EM, JR., BORLAK J, LUCCHESI BR: Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation. J. Cardio-vasc. Pharmacol. (1998) 31:56–66.
   PubMed Web of Science ®Google Scholar
• HAYES E, COURTICE ID, ABRAHAM S, WALKER MJ: Acute toxicity of tedisamil, a new potassium channel blocking drug. Pharmacol. Toxkol. (1993) 73:257–261.
   PubMedGoogle Scholar
• FISCHBACH PS, JOHNSTON PV, FRIEDRICHS GS, LUCCHESI BR: Tedisamil in a chronic canine model of atrial flutter. J. Cardiovasc. Pharmacol. (1999) 34:212–218.
   PubMed Web of Science ®Google Scholar
• BUSCHMANN G, ZEIGLER D, VARCHMIN G, KUHL UG, BEATCH GN, WALKER MJA: An interspecies comparison of the bradycardic activities of tedisamil dihydrochlo-ride. J. Mol. Cell. Cardiol. (1989) 21 (Suppl.
   Google Scholar
• GROHS JG, FISCHER G, RABERGER G: Cardiac andhemodynamic effects of the selective bradycardic agent KC 8857 during exercise-induced myocardial ischemia. Eur. j Pharmacol. (1989) 161:53–60.
   PubMed Web of Science ®Google Scholar
• •First paper to demonstrate the bradycardic effect of tedisamil.
   Google Scholar
• THORMANN J, MITROVIC V, RIEDEL H et al.: Tedisamil (KC 8857) is a new specific bradycardic drug: does it also influence myocardial contractility? Analysis by the conductance (volume) technique in coronary artery disease. Am. Heart J. (1993) 125:1233–1246.
   PubMed Web of Science ®Google Scholar
• DUCHOSAL F, OPIE H: KC8857, a new compound withcombined bradycardic and positive inotropic effects./ Mol. Cell. Cardiol (1987) 19 (Suppl. III):Abstract 19.
   Google Scholar
• FUCHS A, BUSCHMANN G, ZIEGLER D, VARCHIM G, KUHL UG: Tedisamil: cardiac electrophysiologic and functional effects in guinea pigs. Naunyn-Schiedeberg's Arch. Pharmacol. 340:R72.
   Google Scholar
• KREYE VA, PFRUNDER D, THEISS U: Effects of the IC+ channel blocker tedisamil on 86Rb efflux induced by cromakalim, high potassium and noradrenaline and on mechanical tension in rabbit isolated vascular smooth muscle. Naunyn Schmiedebergs Arch. Pharmacol. (1992) 345:238–243.
   PubMed Web of Science ®Google Scholar
• BRAY K, QUAST U: Differential inhibition by tedisamil (KC 8857) and glibenclamide of the responses to cromakalim and minoxidil sulphate in rat isolated aorta. Naunyn Schmiedebergs Arch. Pharmacol. (1992) 345:244–250.
   PubMed Web of Science ®Google Scholar
• DEMOLIS JL, MARTEL C, FUNCK-BRENTANO C, SACHSE A, WEIMANN HJ, JAILLON P: Effects of tedisamil, atenolol and their combination on heart and rate-dependent QTinterval in healthy volunteers. Br]. Clin. Pharmacol. (1997) 44:403–409.
   PubMed Web of Science ®Google Scholar
• MITROVIC V, OEHM E, THORMANN J, PITSCHNER H, HABERBOSCH W: Comparison of the potassium channel blocker tedisamil and the beta-adrenoceptor blocker esmolol and the calcium channel antagonist gallopamil in patients with coronary artery disease. Clin. Cardiol. (1998) 21 :492–502.
   PubMed Web of Science ®Google Scholar
• MITROVIC V, OEHM E, THORMANN J, PITSCHNER H, HAMM C: Potassium channel openers and blockers in coronary artery disease. Comparison to beta-blockers and calcium antagonists. Herz (2000) 25:130–142.
   Google Scholar
• FOX KM, HENDERSON JR, KASKI JC, SACHSE A, KUESTER L, WONNACOTT S: Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker. Heart (2000) 83:167–171.
   PubMed Web of Science ®Google Scholar